Common Contracts
821 similar Underwriting Agreement contracts by 89bio, Inc., Arthur J. Gallagher & Co., Cbre Group, Inc., others
JANUX THERAPEUTICS, INC. (a Delaware corporation) 4,440,851 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,935,483 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 29th, 2024 • Janux Therapeutics, Inc. • Pharmaceutical preparations • New York
CBRE SERVICES, INC. (a Delaware corporation) $500,000,000 5.500% Senior Notes due 2029 UNDERWRITING AGREEMENT Dated: February 20, 2024Underwriting Agreement • February 23rd, 2024 • Cbre Group, Inc. • Real estate • New York
Arthur J. Gallagher & Co. (a Delaware corporation) $500,000,000 5.450% Senior Notes due 2034 $500,000,000 5.750% Senior Notes due 2054 UNDERWRITING AGREEMENTUnderwriting Agreement • February 15th, 2024 • Arthur J. Gallagher & Co. • Insurance agents, brokers & service • New York
MERIDIANLINK, INC. (a Delaware corporation) 6,906,015 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 8th, 2024 • MeridianLink, Inc. • Services-prepackaged software • New York
MeridianLink, Inc., a Delaware corporation (the “Company”), and the persons listed in Schedule B hereto (the “Selling Stockholders”), confirm their respective agreement with Citigroup Global Markets Inc. (“Citi”) and J.P. Morgan Securities LLC (“JPM”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Citi and JPM are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Selling Stockholders, acting severally and not jointly, and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) set forth in Schedules A and B hereto and (ii) the grant by the Selling Stockholders, acting severally and not jointly, to the Underwriters, acting severally and not jointly,
VAXCYTE, INC. (a Delaware corporation) 10,937,500 Shares of Common Stock and Pre-Funded Warrants to Purchase 781,250 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 31st, 2024 • Vaxcyte, Inc. • Biological products, (no disgnostic substances) • New York
FRACTYL HEALTH, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 29th, 2024 • Fractyl Health, Inc. • Surgical & medical instruments & apparatus • New York
THE FORTEGRA GROUP, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 29th, 2024 • Fortegra Group, Inc • Fire, marine & casualty insurance • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • January 18th, 2024 • Inter & Co, Inc. • Commercial banks, nec • New York
Inter & Co, Inc., an exempted company incorporated under the laws of the Cayman Islands with limited liability (the “Company”), confirms its agreement with Goldman Sachs & Co. LLC (“Goldman Sachs”) and BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Goldman Sachs and BofA are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Class A common shares, par value U.S.$0.0000025 per share, of the Company (“Common Shares”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 4,800,000 additional Comm
INVEA THERAPEUTICS, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 12th, 2024 • Invea Therapeutics, Inc • Pharmaceutical preparations • New York
CATALYST PHARMACEUTICALS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 5th, 2024 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
LONGBOARD PHARMACEUTICALS, INC. (Delaware corporation) 10,000,000 Shares of Voting Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 4th, 2024 • Longboard Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
KINETIK HOLDINGS INC. (a Delaware corporation) 6,500,000 Shares of Class A Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 14th, 2023 • Kinetik Holdings Inc. • Natural gas transmission • New York
Kinetik Holdings Inc., a Delaware corporation (the “Company”), and Apache Midstream LLC, a Delaware limited liability company, (the “Selling Stockholder”), confirm their respective agreements with J.P. Morgan Securities LLC (“J.P. Morgan”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom J.P. Morgan is acting as representative (in such capacity, collectively, the “Representative”), with respect to: (i) the sale by the Selling Stockholder of up to 6,500,000 shares of Class A common stock of the Company, par value $0.0001 per share (the “Common Stock”) and (ii) the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock set forth in Schedule A (which includes shares of Common Stock to be allocated to certain officers and directors of the Company (the “Affiliated Purcha
89BIO, INC. (a Delaware corporation) 15,135,135 Shares of Common Stock Pre- Funded Warrants to Purchase 1,081,081 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 8th, 2023 • 89bio, Inc. • Pharmaceutical preparations • New York
ARHAUS, INC. (a Delaware corporation) 12,000,000 Shares of Class A Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 18th, 2023 • Arhaus, Inc. • Retail-furniture stores • New York
QuantumScape Corporation (a Delaware corporation) 37,500,000 Shares of Class A Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 8th, 2023 • QuantumScape Corp • Miscellaneous electrical machinery, equipment & supplies • New York
PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) 4,422,169 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 4th, 2023 • PROCEPT BioRobotics Corp • Surgical & medical instruments & apparatus • New York
TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 5,714,285 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 2nd, 2023 • Tarsus Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with Goldman Sachs & Co. LLC (“Goldman”), BofA Securities, Inc. (“BofA”), Guggenheim Securities, LLC (“Guggenheim”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Goldman, BofA and Guggenheim are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 857,142 additional shares of Common Stock. The afo
INOZYME PHARMA, INC. (a Delaware corporation) 12,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 28th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations • New York
ACUMEN PHARMACEUTICALS, INC. (a Delaware corporation) 16,774,193 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 20th, 2023 • Acumen Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Acumen Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), Citigroup Global Markets Inc. (“Citi”) and Stifel, Nicolaus & Company, Incorporated (“Stifel”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA, Citi and Stifel are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 2,516,128 additional shares of Common Sto
JANUX THERAPEUTICS, INC. (a Delaware corporation) 4,153,717 Shares of Common Stock and Pre-Funded Warrants to Purchase 583,483 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 18th, 2023 • Janux Therapeutics, Inc. • Pharmaceutical preparations • New York
Janux Therapeutics, Inc., a Delaware corporation (the “Company”) confirms its agreement with BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA is acting as representative (in such capacity, the “Representative”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) and pre-funded warrants to purchase shares of Common Stock at an exercise price equal to $0.001 per share (the “Pre-Funded Warrants”), set forth in Schedule A hereto. The 4,153,717 shares of Common Stock (the “Initial Securities”) and 583,483 Pre-Funded Warrants to be purchased by the Underwriters are herein called, collectively, the “Securities.” The shares of C
CARIBOU BIOSCIENCES, INC. (a Delaware corporation) 19,230,769 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 17th, 2023 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
Caribou Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), SVB Securities LLC (“Leerink Partners”), Evercore Group L.L.C. (“Evercore”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA, Leerink Partners and Evercore are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth opposite such Underwriters’ respective names in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 19,2
Turnstone Biologics Corp. (a Delaware corporation) [ ] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 17th, 2023 • Turnstone Biologics Corp. • Biological products, (no disgnostic substances) • New York
CBRE SERVICES, INC. (a Delaware corporation) $1,000,000,000 5.950% Senior Notes due 2034 UNDERWRITING AGREEMENT Dated: June 20, 2023Underwriting Agreement • June 23rd, 2023 • Cbre Group, Inc. • Real estate • New York
Elevation Oncology, Inc. (a Delaware corporation) 17,810,000 Shares of Common Stock Pre-funded Warrants to Purchase 4,440,000 Shares of Common Stock and Common Warrants to Purchase 22,250,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 9th, 2023 • Elevation Oncology, Inc. • Biological products, (no disgnostic substances) • New York
LUCID GROUP, INC. (a Delaware corporation) 173,544,948 Shares of Class A Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 5th, 2023 • Lucid Group, Inc. • Motor vehicles & passenger car bodies • New York
Lucid Group, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA Securities, Inc. is acting as representative (in such capacity, the “Representative”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Class A Common Stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto. The aforesaid 173,544,948 shares of Common Stock are herein called the “Securities.” If there is only one Underwriter listed on Schedule A, the term Representative as used herein shall mean you, as Underwriter, and the term Underwriters shall mean either the singular or plural as the context requires.
HOOKIPA PHARMA INC. (a Delaware corporation) 22,900,768 Shares of Common Stock 15,268 Shares of Series A-2 Convertible Preferred Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 2nd, 2023 • HOOKIPA Pharma Inc. • Pharmaceutical preparations • New York
Oculis Holding AG (a stock corporation (Aktiengesellschaft) incorporated and existing under the laws of Switzerland) 3,500,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • June 1st, 2023 • Oculis Holding AG • Pharmaceutical preparations • New York
Oculis Holding AG, a stock corporation (Aktiengesellschaft) incorporated and existing under the laws of Switzerland (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), SVB Securities LLC (“SVB Securities”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA and SVB Securities are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of ordinary shares, nominal value CHF 0.01 per share, of the Company (“Ordinary Shares”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 525,000 additional Ordinary Shar
a Nevada corporation) 1,666,667 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 25th, 2023 • U S Physical Therapy Inc /Nv • Services-health services • New York
INTAPP, INC. (a Delaware corporation) 6,250,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 19th, 2023 • Intapp, Inc. • Services-prepackaged software • New York
Intapp, Inc., a Delaware corporation (the “Company”), and the persons listed in Schedule B hereto (the “Selling Shareholders”), confirm their respective agreements (this “Agreement”) with BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA is acting as Representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company and the Selling Shareholders, acting severally and not jointly, and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) set forth in Schedules A and B hereto and (ii) the grant by certain of the Selling Shareholders (the “Option Selling Shareholders”), acting severally and not jointly, to the Underwriters, acting several
VAXCYTE, INC. (a Delaware corporation) 11,200,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 20th, 2023 • Vaxcyte, Inc. • Biological products, (no disgnostic substances) • New York
MDNA Life Sciences Inc. (a Delaware corporation) Shares of Common Stock Warrants to Purchase Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 3rd, 2023 • MDNA Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York
89BIO, INC. (a Delaware corporation) 16,923,077 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 28th, 2023 • 89bio, Inc. • Pharmaceutical preparations • New York
GOLDMAN SACHS BDC, INC. (a Delaware corporation) 6,500,000 Shares of Common Stock (Par Value $0.001 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • March 9th, 2023 • Goldman Sachs BDC, Inc. • New York
Verisk Analytics, Inc. (a Delaware corporation)Underwriting Agreement • March 7th, 2023 • Verisk Analytics, Inc. • Services-computer processing & data preparation • New York
Verisk Analytics, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and HSBC Securities (USA) Inc. (“HSBC”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA and HSBC are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company, and the purchase by the Underwriters, acting severally and not jointly, of $500,000,000 aggregate principal amount of the Company’s 5.750% Senior Notes due 2033 (the “Securities”). The Securities will be issued pursuant to the Base Indenture, dated as of March 6, 2019 (the “Base Indenture”) between the Company and Wells Fargo Bank, National Association, as trustee (the “Trustee”), as supplemented by a Supplemental Indenture, to be dated as of March 2, 2023 (the “Supplemental Indenture” an
Arthur J. Gallagher & Co. (a Delaware corporation) $350,000,000 5.500% Senior Notes due 2033 $600,000,000 5.750% Senior Notes due 2053 UNDERWRITING AGREEMENTUnderwriting Agreement • March 2nd, 2023 • Arthur J. Gallagher & Co. • Insurance agents, brokers & service • New York
